To the content
2 . 2022

Gestagens in high-risk pregnancy

AbstractOne of the main ways to overcome reproductive losses in a difficult demographic situation is to provide effective drug and non-drug assistance for successful maternity, its maintenance and live birth. Decision-making on usage of any pharmacological therapy should be based on a comprehensive analysis of all available scientific evidence, its effectiveness and safety, on a specific clinical situation, as well as on the availability of the drug in a particular country. The only class of drugs that is recommended for all types of threatened and habitual miscarriage are progestogens, which have a solid evidence base. In Russia, during pregnancy, according to indications, patients most often receive dydrogesterone or progesterone preparations. The accumulated huge array of clinical data on the efficacy and safety of dydrogesterone in high-risk pregnancy (including data from direct comparative studies) allows us to consider it as the progestogen of choice in early pregnancy.

Keywords:refractory pregnancy loss; habitual abortion; gestagens; dydrogesterone

Funding. The study had no sponsor support.

Conflict of interest. The authors declare no conflict of interest.

For citation: Tetruashvili N.K., Serov V.N. Gestagens in high-risk pregnancy. Akusherstvo i ginekologiya: novosti, mneniya, obu-chenie [Obstetrics and Gynecology: News, Opinions, Training]. 2022; 10 (2): 31-8. DOI: https://doi.org/10.33029/2303-9698-2022-10-2-31-38 (in Russian)

REFERENCES

1. Markelova E.V., Tulupova M.S., Khamoshina M.B., Chepurnova N.S., Nevezhkina T.A. The role of male factor in pregnancy loss. Problemy reproduktsii [Problems of Reproduction]. 2020; 26 (4): 85-90. DOI: https://doi.org/10.17116/repro20202604185 (in Russian)

2. Quenby S., Gallos I.D., Dhillon-Smith R.K., et al. Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss. Lancet. 2021; 397 (10 285): 1658-67. DOI: https://doi.org/10.1016/S0140-6736(21)00682-6

3. Devall A.J., Papadopoulou A., Podesek M., et al. Progestogens for preventing miscarriage: a network meta-analysis. Cochrane Database Syst Rev. 2021; 4: CD013792.

4. Haas D.M., Hathaway T.J., Ramsey P.S. Progestogen for preventing miscarriage in women with recurrent miscarriage of unclear etiology. Cochrane Database Syst Rev. 2019; 11: CD003511.

5. Wahabi H.A., Fayed A.A., Esmaeil S.A., et al. Progestogen for treating threatened miscarriage. Cochrane Database Syst Rev. 2018; 8: CD005943.

6. Cohain J.S., Buxbaum R.E., Mankuta D. Spontaneous first trimester miscarriage rates per woman among parous women with 1 or more pregnancies of 24 weeks or more. BMC Pregnancy Childb. 2017; 17 (1): 437.

7. Nikitin AI. Offspring’s health after IVF (literature review). Problemy reproduktsii [Problems of Reproduction]. 2019; 25 (3): 28-33. DOI: https://doi.org/10.17116/repro20192503128 (in Russian)

8. Tournaye H., Sukhikh G.T., Kahler E., Griesinger G. A phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization. Hum Reprod. 2017; 32 (5): 1019-27.

9. Tetruashvili N.K., Agadzhanova A.A. Management of single and multiple pregnancy in women with habitual abortion. Akusherstvo i ginekologiya: novosti, mneniya, obuchenie [Obstetrics and Gynecology: News, Opinions, Training]. 2018; (2): 52-7. DOI: https://doi.org/10.24411/2303-9698-2018-00015 (in Russian)

10. Stol’nikova 1.1., Evstifeeva E.A., Filippchenkova S.I., Murashova L.A., Do-sova S.Yu. Quality of life in patients with recurrent miscarriage. Psikhologiya. Psik-hofiziologiya. [Psychology. Psychophysiology]. 2021; 14 (2): 89-95. DOI: https://doi.org/10.14529/ipps210209 (in Russian)

11. Cumming G., Klein S., Bolsover D., Lee A., Alexander D., Maclean M., et al. The emotional burden of miscarriage for women and t heir partners: trajectories of anxiety and depression over 13 months. BJOG. 2007; 114: 1138-45.

12. Engelhard I.M., van den Hout M.A., Arntz A. Posttraumatic stress disorder after pregnancy loss. Gen Hosp Psychiatry. 2001; 23 (2): 62-6. DOI: https://doi.org/10.1016/s0163-8343(01)00124-4

13. Guidelines for assessing the scientific validity of the information included in clinical recommendations. FGBU “CEKKMP” of the Ministry of Health of Russia. 2019.URL: https://rosmedex.ru/wp-content/uploads/2019/10/mr_nauch-obosn-kr.pdf (in Russian)

14. Christiansen O.B., Nybo Andersen A.M., Bosch E., et al. Evidence-based investigations and treatments of recurrent pregnancy loss. Fertil Steril. 2005; 83 (4): 821-39.

15. Tetruashvili N.K. Habitual miscarriage. Akusherstvo i ginekologiya: novosti, mneniya, obuchenie [Obstetrics and Gynecology: News, Opinions, Training]. 2017; (4): 70-87. DOI: https://doi.org/10.24411/2303-9698-2017-00010 (in Russian)

16. Kuroda K., Ikemoto Y., Horikawa T., et al. Novel approaches to the management of recurrent pregnancy loss: The OPTIMUM (OPtimization of Thyroid function, Thrombophilia, Immunity, and Uterine Milieu) treatment strategy. Reprod Med Biol. 2021; 20 (4): 524-36. Epub 2021 Sep 14. DOI: https://doi.org/10.1002/rmb2.12412

17. Apolikhina I.A., Shneyderman M.G., Teterina T.A., Gorbunova E.A. Reasons of recurrent miscarriage. Ginekologiya [Gynecology]. 2013; 15 (5): 60-5. (in Russian)

18. Evans R.M. The steroid and thyroid hormone receptor superfamily. Science. 1988; 240 (4854): 889-95.

19. Griesinger G., Tournaye H., Macklon N., et al. Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction. Reprod Biomed Online. 2019; 38 (2): 249-59.

20. Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005; 8 (suppl 1): 3-63.

21. Raghupathy R., Szekeres-Bartho J. Progesterone: a unique hormone with immunomodulatory roles in pregnancy. Int J Mol Sci. 2022; 23 (3): 1333. DOI: https://doi.org/10.3390/ijms23031333 PMID: 35163255; PMCID: PMC8835837.

22. Katalinic A., Shulman L.P., Strauss J.F., Garcia-Velasco J.A., van den Anker J.N. A critical appraisal of safety data of dydrogesterone for the support of early pregnancy: a scoping review and meta-analysis. Reprod Biomed Online. 2022. DOI: https://doi.org/10.1016/j.rbmo.2022.03.032

23. Chakravarty B.N., Shirazee H.H., Dam P., et al. Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. J Steroid Biochem Mol Biol. 2005; 97 (5): 416-20.

24. van der Linden M., Buckingham K., Farquhar C., et al. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev. 2015; 7: CD009154.

25. Stanczyk F.Z., Hapgood J.P., Winer S., et al. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev. 2013; 34 (2): 171-208.

26. Instructions for medical use of the drug Duphaston® dated February 14, 2022 (in Russian)

27. Instructions for the medical use of the drug Utrozhestan® dated February 24, 2021. (in Russian)

28. Sator M., Radicioni M., Cometti B., et al. Pharmacokinetics and safety profile of a novel progesterone aqueous formulation administered by the s.c. route. Gynecol Endocrinol. 2013; 29 (3): 205-8.

29. Vaisbuch E., Leong M., Shoham Z. Progesterone support in IVF: is evidence-based medicine translated to clinical practice? A worldwide web-based survey. Reprod Biomed Online. 2012; 25 (2): 139-45.

30. Miscarriage. Clinical guidelines ROAG, 2021. ID: 670. (in Russian)

31. Isthmic-cervical insufficiency. Clinical guidelines ROAG, 2021. ID: 671. (in Russian)

32. Normal pregnancy. Clinical guidelines ROAG, 2020. ID: 288. (in Russian)

33. Habitual miscarriage. Clinical guidelines ROAG, 2022. ID: 721 (in Russian)

34. Female infertility. Clinical guidelines ROAG. 2021. ID: 641 (in Russian)

35. Ectopic pregnancy and miscarriage: diagnosis and initial management. NICE Guideline [NG126]. Epub 2019 April 17. Last updated: 2021 Nov 24.

36. Recurrent pregnancy loss. Guideline of the European Society of Human Reproduction and Embryology 2017. Updated: 2017 Nov.

37. Toth B., Wiirfel W., Bohlmann M., et al. Recurrent miscarriage: diagnostic and therapeutic procedures. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry Number 015/050). Geburtshilfe Frauenheilkd. 2018; 78 (4): 364-81. DOI: https://doi.org/10.1055/a-0586-4568

38. American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2015; 103 (3): e9-17. DOI: http://doi.org/10.1016/j.fertnstert.2014.12.093

39. The Royal Australian College of General Practitioners. AJGP. 2018; 47 (7).

40. Repina M.A., Bobrov S.A. The role of progestogens in obstetric practice. Zhurnal akusherstva i zhenskikh bolezney [Journal of Obstetrics and Women’s Diseases]. 2013; 62 (3): 65-9. (in Russian)

41. Griesinger G., Blockeel C., Kahler E., Pexman-Fieth C., Olofsson J.I., Driessen S., et al. Dydrogesterone as an oral alternative to vaginal progesterone for IVF luteal phase support: A systematic review and individual participant data meta-analysis. PLoS One. 2020; 15 (11): e0241044. DOI: https://doi.org/10.1371/journal.pone.0241044

42. Coomarasamy A., Devall A.J., Brosens J.J., et al. Micronized vaginal progesterone to prevent miscarriage: a critical evaluation of randomized evidence. Am J Obstet Gynecol. 2020; 223 (2): 167-76.

43. Serov V.N. Commentary on the article «The use of oral progestogen in women with threatened miscarriage in the first trimester: a randomized, double-blind, placebo-controlled study». Akusherstvo i ginekologiya [Obstetrics and Gynecology]. Epub 2021 Jan 18. URL: https://aig-journal.ru/content/news/Primenenie-peroralnogo-ge-stagena-u-jenshin-s-ugrojaushim-vykidyshem-v-pervom-trimestre-randomizirovannoe-dvoinoe-slepoe-placebo-kontroliruemoe-issledovanie-Kommentarii-redakcii.html (in Russian)

44. Diana Man Ka Chan, Ka Wang Cheung, Jennifer Ka Yee Ko, Sofie Shuk Fei Yung, Shui Fan Lai, Mei Ting Lam, et al. Use of oral progestogen in women with threatened miscarriage in the first trimester: a randomized double-blind controlled trial. Hum Reprod. 2020; 36 (3): deaa327. DOI: https://doi.org/10.1093/humrep/deaa327

45. D’yakonov S.A., Raevskaya O.A. Evidence-based medicine: contraversions of thoughtless trust. StatusPraesens. Ginekologiya, akusherstvo, besplodniy brak [StatusPraesens. Gynecology, Obstetrics, Barren Marriage]. 2021; (2): 38-44. (in Russian)

46. Zhao H., He W., Yang Z. A pairwise and network meta-analysis comparing the efficacy and safety of progestogens in threatened abortion. Int J Gynaecol Obstet. 2022; 156 (3): 383-93. PMID: 33864694.

47. Lee H.J., Park T.C., Kim H.J., et al. The influence of oral dydrogesterone and vaginal progesterone on threatened abortion: a systematic review and meta-analysis. Biomed Res Int. 2017; 2017: 1-10. DOI: https://doi.org/10.1155/2017/3616875.

48. Wang X.X., Luo Q., Bai W.P. Efficacy of progesterone on threatened miscarriage: Difference in drug types. J Obstet Gynaecol Res. 2019; 45 (4): 794-802. DOI: https://doi.org/10.1111/jog.13909

49. Li L., Zhang Y., Tan H., et al. Effect of progestogen for women with threatened miscarriage: a systematic review and meta-analysis. BJOG. 2020; 127 (9): 1055-63.

50. Pandian R.U. Dydrogesterone in threatened miscarriage: a Malaysian experience. Maturitas. 2009; 65 (suppl 1): S47-50.

51. Kumar A., Begum N., Prasad S., et al. Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind, randomized, parallel, placebo-controlled trial. Fertil Steril. 2014; 102 (5): 1357-63.e3.

52. Kale A.R., Kale A.A., Yelikar K. A comparative, randomized control trial in patients of per vaginal bleeding comparing efficacy of oral dydrogesterone versus vaginal progesterone in successful pregnancy outcome for patients with recurrent pregnancy loss. J Obstet Gynaecol India. 2021; 71 (6): 591-5. DOI: https://doi.org/10.1007/s13224-021-01473-2

53. Astrakhantseva M.M., Myasoutova A.I., Breusenko L.E., et al. Pregnancy loss. Treatment options. Voprosy ginekologii, akusherstva i perinatologii [Problems of Gynecology, Obstetrics and Perinatology]. 2021; 20 (2): 75-84. DOI: https://doi.org/10.20953/1726-1678-2021-2-75-84 (in Russian)

54. Bespalova O.N., Butenko M.G., Bakleycheva M.O., Kosyakova O.V., Sarg-syan G.S., Kogan I.Yu. Efficacy of progestogens in the management of threatened miscarriage in women with multiple pregnancies resulting from assisted reproductive technologies. Voprosy ginekologii, akusherstva i perinatologii [Problems of Gynecology, Obstetrics and Perinatology]. 2021; 20 (1): 47-54. DOI: https://doi.org/10.20953/1726-1678-2021-1-47-54 (in Russian)

55. Tskhay V., Schindler A., Shestakova M., Klimova O., Narkevich А. The role of progestogen supplementation (dydrogesterone) in the prevention of preeclampsia. Gynecol Endocrinol. 2019; 36 (8): 698-701. DOI: https://doi.org/10.1080/09513590.2019.1706085

56. Ozer G., Yuksel K.B., Yucel Cicek O.S., Kahraman S. Oral dydrogesterone vs micronized vaginal progesterone gel for luteal phase support in frozen-thawed single blastocyst transfer in good prognosis patients. J Gynecol Obstet Hum Reprod. 2021; 50 (5): 102030. DOI: https://doi.org/10.1016/jJogoh.2020.102030

57. ART: strategy choice. Innovatsionnaya farmakoterapiya [Innovative Pharmacotherapy]. 2021; (3): 30-4. URL: https://www.innofarma.ru/index.php?id=111 (in Russian)

58. Vidal A., Dhakal C., Weiss J., Lehnick D., Koh A. P-654 What is the best luteal phase support in frozen-thawed embryo transfer cycle? Hum Reprod. 2021; 36 (suppl 1): deab130.653. DOI: https://doi.org/10.1093/humrep/deab130.653

59. Kvashnina E.V., Tutakov M.A., Vakhlova O.S., Tomina E.V., Shilova N.V. Preimplantation genetic testing for aneuploidy in various protocols of assisted reproductive technologies with vitrified embryo. Akusherstvo i ginekologiya [Obstetrics and Gynecology]. 2021; (3): 175-82. DOI: https://doi.org/10.18565/aig.2021.3.175-182 (in Russian)

60. Mor G., Aldo P., Alvero A.B. The unique immunological and microbial aspects of pregnancy. Nat Rev Immunol. 2017; 17 (8): 469-82. DOI: 10.1038/nri.2017.64

61. Carp H.J.A. Progestogens and pregnancy loss. Climacteric. 2018; 21 (4): 380-4. DOI: 10.1080/13697137.2018.1436166

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITORS
CHIEF EDITOR
Sukhikh Gennadii Tikhonovich
Academician of the Russian Academy of Medical Sciences, V.I. Kulakov Obstetrics, Gynecology and Perinatology National Medical Research Center of Ministry of Healthсаre of the Russian Federation, Moscow
CHIEF EDITOR
Kurtser Mark Arkadievich
Academician of the Russian Academy of Sciences, MD, Professor, Head of the Obstetrics and Gynecology Subdepartment of the Pediatric Department, N.I. Pirogov Russian National Scientific Research Medical University, Ministry of Health of the Russian Federation
CHIEF EDITOR
Radzinsky Viktor Evseevich
Corresponding Member of the Russian Academy of Sciences, MD, Professor, Head of the Subdepartment of Obstetrics and Gynecology with a Course of Perinatology of the Medical Department in the Russian People?s Friendship University

Journals of «GEOTAR-Media»